SCHEMBL2244849

SCHEMBL2244849

CCS(=O)(=O)c1nc2ccccc2o1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.50
GAA P10253 1/20 0.50
ALOX15 P16050 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
MAPT P10636 2/20 0.47
NPC1 O15118 2/20 0.47
RAB9A P51151 2/20 0.47
NAAA Q02083 1/20 0.44
XDH P47989 1/20 0.44
SMN1; SMN2 Q16637 3/20 0.43
TP53 P04637 2/20 0.43
ALDH1A1 P00352 1/20 0.43
PTGS2 P35354 1/20 0.42
LOXL2 Q9Y4K0 1/20 0.42
CYP1A2 P05177 1/20 0.42
AHR P35869 1/20 0.42
UTRN P46939 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL305334 0.81 LMNA (0.53) LMNAGAAALOX15TDP1MAPT
SCHEMBL329398 0.79 MAPT (0.47) LMNAGAAALOX15TDP1MAPT
SCHEMBL29265224 0.79 LMNA (0.41) LMNAGAAALOX15TDP1MAPT
SCHEMBL329399 0.78 MAPT (0.46) LMNAGAAALOX15TDP1MAPT
SCHEMBL544259 0.78 MAPT (0.46) LMNAGAAALOX15TDP1MAPT
SCHEMBL31665885 0.78 MAPT (0.46) LMNAGAAALOX15TDP1MAPT
SCHEMBL3136339 0.78 MAPT (0.46) LMNAGAAALOX15TDP1MAPT
SCHEMBL27609035 0.78 KMT2A (0.42) LMNAGAAALOX15TDP1MAPT
SCHEMBL9380534 0.78 LMNA (0.43) LMNAGAAALOX15TDP1MAPT
SCHEMBL15157903 0.77 MAPT (0.46) LMNAGAAALOX15TDP1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220274968-A1 Oxazole And Oxadiazole Derivatives Useful As Agonists Of Free Fatty Acid Receptor 1 GBIOTECH S.À.R.L. (CH) 2022-09-01 US disclosed
US-8501713-B2 Drug combinations for the treatment of duchenne muscular dystrophy SUMMIT CORPORATION PLC (GB) 2013-08-06 US disclosed
US-20110195932-A1 Drug Combinations for the Treatment of Duchenne Muscular Dystrophy SUMMIT (OXFORD) LIMITED (GB) 2011-08-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110195932-A1 Drug Combinations for the Treatment of Duchenne Muscular Dystrophy PYGM, CPT1B, GYS1 LMNA 260/4885GAA 37/4885ALOX15 2726/4885
US-20220274968-A1 Oxazole And Oxadiazole Derivatives Useful As Agonists Of Free Fatty Acid Receptor 1 FFAR2, FFAR1, FFAR3 LMNA 4289/4885GAA 2875/4885ALOX15 111/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.